Pipeline

Overview

Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUBs inhibitors for a number of significant clinical indications.

We are currently prioritizing four lead DUB target programs that are based on extensive research around the ~100 human DUBs and their market opportunities.

Our world-leading drug discovery and development platform gives us the opportunity to explore multiple additional DUB targets of relevance to other disease indications, both in-house and through partnerships with other pharmaceutical companies.

Several of our USP30 inhibitor programs are in pre-clinical development.

ResearchPreclinicalPhase I

DUB program: USP30 Inhibitor (learn more)
Rationale/target: Increased mitophagy
Therapeutic indication: Mitochondrial diseases

DUB program: USP30 Inhibitor (learn more)
Rationale/target: Increased mitophagy
Therapeutic indication: Peripheral USP30 indication

DUB program: USP30 Inhibitor (learn more)
Rationale/target: Increased Mitophagy
Therapeutic indication: Neurodegeneration/Parkinson’s

DUB program: Cezanne-1 (learn more)
Rationale/target: Inhibition of Th-17 immune responses
Therapeutic indication: Inflammation

DUB program: UCHL1 (learn more)
Rationale/target: Inhibition of myofibroblast
Therapeutic indication: Fibrosis

DUB program: USP7 Inhibitor (learn more)
Rationale/target: Increased FOXP3 degradation
Therapeutic indication: Immuno-oncology setting